ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|

Trending News

The Muscle-Brain Connection in ME/CFS Revealed

The Neurobiology of ME/CFS

Interview: Jennifer Brea Talks About Obstacles, Adjustments, and Inspiration

DNA Methylation Modifications Associated with Chronic Fatigue Syndrome

Adrenal Burnout? Naturally Boost Your Energy & Manage Stress

Smartphone app and specialised clinic for chronic fatigue patients

Curcumin Made 65X More Bioavailable - Modern Take on a "Golden" Spice Busts Brain Fog, Joint & Body ...

Post-Exertional Debility is an Important Symptom during Myalgic Encephalomyelitis

VIDEO: Dr. Newton Talks About Biomarkers and the Future of ME/CFS Treatment

Stress management skills, cortisol awakening response, and post-exertional malaise in Chronic Fatigu...

 
Print Page
Email Article

Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome

  [ 1 vote ]   [ Discuss This Article ]
www.ProHealth.com • August 21, 2013


Editor's comment: Cyclobenzaprine is probably best known by the brand name Flexeril, which is currently classified as a muscle relaxant. 

Data Elucidate Cyclobenzaprine as a Serotonin and Norepinephrine Receptor Antagonist and Reuptake Inhibitor (SNARI)

NEW YORK, NY – August 19, 2013 – Tonix Pharmaceuticals Holding Corp. (TNXP), a specialty pharmaceutical company developing novel treatments for challenging disorders of the central nervous system (CNS), including fibromyalgia and post-traumatic stress disorder (PTSD), presented results from nonclinical studies of cyclobenzaprine (CBP), the active ingredient of Tonix's lead candidate, TNX-102 sublingual tablet (TNX-102 SL), at the International Pain Society's Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome in Seattle, Washington.

The presentation, titled "Cyclobenzaprine (CBP) Inhibits Serotonin (5HT) Receptor Type 2A, Adrenergic Receptor alpha1A and the 5HT and Norepinephrine (NE) Reuptake Transporters: Mechanistic Implications for Treating Fibromyalgia Syndrome and Post-traumatic Stress Disorder (PTSD) by Improving Sleep Quality," was given by Bruce Daugherty, Ph.D., Tonix's Chief Scientific Officer and the study's lead author, on Friday, August 16, at 1:45 PM Pacific Time.

As observed in nonclinical studies conducted under Tonix's direction, CBP and its major metabolite, norcyclobenzaprine (nCBP), exhibited potent binding (Ki) to certain CNS receptors including 5HT2A (5.2 and 13 nM, respectively), adrenergic alpha1A (5.6 and 34 nM), and histamine H1 (1.3 and 5.9 nM). In addition, CBP and nCBP are functional antagonists (IC50) at 5HT2A (230 and 140 nM, respectively), alpha1A (4.9 and 16 nM, respectively), and H1 (5.2 and 16 nM, respectively). CBP and nCBP also exhibited potent binding to the serotonin (35 and 2.6 nM, respectively) and norepinephrine (29 and 91 nM, respectively) monoamine reuptake transporters.

Dr. Daugherty commented, "We have significantly advanced our understanding of the mechanisms of action of CBP in the CNS. We have shown that CBP exerts multiple effects on serotonergic and adrenergic neurotransmission. As a Serotonin and Norepinephrine Receptor Antagonist and Reuptake Inhibitor, or SNARI, we believe TNX-102 SL exerts pharmacological effects distinct from those exerted by products approved by the Food and Drug Administration for the management of fibromyalgia and PTSD. We look forward to commencing our Phase 2b/3 trial of TNX-102 SL in patients with fibromyalgia this quarter." 

About Tonix Pharmaceuticals Holding Corp. Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. The Company seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix's lead pharmaceutical candidate, TNX-102 SL, targets central pain. Fibromyalgia is a central pain syndrome, and central pain is a component of post-traumatic stress disorder. Tonix applies its core technology toward the treatment of central pain by increasing the restorative power of sleep. To learn more, please visit www.tonixpharma.com.

Source: Tonix Pharmaceuticals, Press Release, August 19, 2013.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products

MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Live Longer: Groundbreaking Research on Omega-3s Live Longer: Groundbreaking Research on Omega-3s
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
The Brain Boosting and Fatigue Fighting B-12 The Brain Boosting and Fatigue Fighting B-12
Itching to Find Dry Skin Relief? Itching to Find Dry Skin Relief?
Preserving Cognitive Function with Aging Preserving Cognitive Function with Aging

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing